Navigation Links
Gen-Probe to Acquire Tepnel Life Sciences, Fast-Growing European Molecular Diagnostics Company, for 92.8 Million Pounds Sterling ($132.2 Million) in Cash
Date:1/30/2009

e and marketing of rapid, accurate and cost-effective nucleic acid tests (NATs) that are used primarily to diagnose human diseases and screen donated human blood. Gen-Probe has approximately 25 years of NAT expertise, and received the 2004 National Medal of Technology, America's highest honor for technological innovation, for developing NAT assays for blood screening. Gen-Probe is headquartered in San Diego and employs approximately 1,000 people. For more information, go to www.gen-probe.com.

About Non-GAAP Financial Measures

This announcement contains certain financial measures that are not calculated in accordance with U.S. GAAP, including non-GAAP EPS. Non-GAAP EPS excludes all non-cash charges such as intangible amortization and stock compensation expense, as well as transaction expenses. Gen-Probe's management believes these U.S. non-GAAP financial measures provide Gen-Probe investors meaningful supplemental information regarding the expected financial results of the acquisition.

Tepnel has not reconciled its historical financial statements to U.S. GAAP. All pro forma combined financial information in this press release is based upon a combination of Gen-Probe historical and projected financial information, prepared in accordance with U.S. GAAP, and Tepnel's historical and projected financial information, prepared in accordance with IFRS. Based on Gen-Probe's preliminary analysis, the Company does not anticipate material adjustments to reconcile U.S. GAAP with IFRS.

Caution Regarding Forward-Looking Statements

Any statements in this press release relating to Gen-Probe's offer and the Company's expectations, beliefs, plans, objectives, assumptions or future events or performance are not historical facts and are forward-looking statements. These statements are often, but not always, made thr
'/>"/>

SOURCE Gen-Probe Incorporated
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine news :

1. Gen-Probe and Novartis Agree to Extend and Expand Blood Screening Collaboration
2. Eric Tardif Joins Gen-Probe as Senior Vice President, Corporate Strategy
3. Gen-Probe to Webcast Presentation at the 27th Annual J.P. Morgan Healthcare Conference
4. Gen-Probe to Webcast Presentation at the 20th Annual Piper Jaffray Health Care Conference
5. Gen-Probe Reports Strong Financial Results for Third Quarter 2008, Raises Full-Year EPS Guidance
6. Gen-Probe Announces Webcasts of Three Upcoming Investor Events
7. Gen-Probe to Webcast Two Upcoming Investor Presentations
8. Gen-Probe Announces Webcast of First Quarter 2008 Earnings Conference Call
9. Gen-Probe to Webcast Presentation at Leerink Swann Molecular Diagnostics Conference
10. Gen-Probe to Webcast Presentation at Deutsche Bank Small- and Mid-Cap Growth Conference
11. Gen-Probe to Webcast Presentation at 26th Annual JPMorgan Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/30/2014)... (PRWEB) October 30, 2014 Home Care ... leading provider of non-medical, in-home senior care, is weighing ... increased brain health. , The study, performed by the ... of 60 and 78 over a week-long period and ... to daily physical activity. By examining the structural soundness ...
(Date:10/30/2014)... Fort Lauderdale, FL (PRWEB) October 30, 2014 ... leading US Joint Commission Accredited teleradiology and specialty ... today that in addition to its existing teleradiology ... adding multispecialty second opinion and expert telemedicine services, ... Houston, Texas. , As a result of this ...
(Date:10/30/2014)... The Woodlands, TX (PRWEB) October 30, 2014 ... hospital system, released today its 2014 third quarter ... hospitals across Texas boasted infection rates of only ... also reported patient satisfaction scores exceeding 98 percent. ... this past quarter, which included rising satisfaction scores,” ...
(Date:10/30/2014)... Norton HealthDay Reporter WEDNESDAY, ... plastics, chemical during pregnancy may have effects on genital development ... that baby boys born to moms with greater exposure to ... distance -- the space between the genitals and anus. Anogenital ... marker of exposure to androgens ("male" hormones) during pregnancy. ...
(Date:10/30/2014)... (HealthDay News) -- Americans, opinions about the Affordable Care ... study finds. Democratic voters are strongly in favor ... researchers. Almost three-quarters of Democrats want the next Congress ... Congress to implement the current law, while 44 percent ... Among Independent voters, one-third want the law repealed, and ...
Breaking Medicine News(10 mins):Health News:Home Care Assistance – Halton/Peel Region, a Top Provider of In-Home Care, Responds to Study Linking Exercise to Healthier Senior Brains 2Health News:Home Care Assistance – Halton/Peel Region, a Top Provider of In-Home Care, Responds to Study Linking Exercise to Healthier Senior Brains 3Health News:USARAD HOLDINGS INC, SECONDOPINIONS.COM® Pioneers Specialty On-Demand Telemedicine And Second Opinion Service At Houston-Based, Mission Bend Freestanding ER Chain 2Health News:USARAD HOLDINGS INC, SECONDOPINIONS.COM® Pioneers Specialty On-Demand Telemedicine And Second Opinion Service At Houston-Based, Mission Bend Freestanding ER Chain 3Health News:Victory Healthcare Releases Q3 Satisfaction, Infection Rates 2Health News:Victory Healthcare Releases Q3 Satisfaction, Infection Rates 3Health News:Plastics' Chemical May Affect Baby Boys' Genital Development 2Health News:Plastics' Chemical May Affect Baby Boys' Genital Development 3Health News:Voters' Views on Obamacare Split Along Party Lines 2
... is one step in a long, slow process of reproductive ... age 40 and declining levels of the hormones estrogen and ... a female., ,Menopause, or the “change of life,” affects ... help women cope up better with menopause, hormone replacement therapy ...
... declared Tuberculosis as an emergency in Africa. It is ... WHO Regional // Committee for Africa comprising health ministers ... in the African region. The deaths have quadrupled in ... adopted today at the end of the Committee's fifty-fifth ...
... expression responsible for extreme farsightedness in people. , ... rare, potentially blinding disorder, is caused // by an ... eye growth and regulates the organ's shape and focus. ... the journal Proceedings of the National Academy of Sciences., ...
... probe for the treatment of brain cancer is the ... of Neurological Disorders at Manipal Hospital in Bangalore. // ... ,Removal of brain tumors surgically leads to enormous ... depends on the surgeon’s skill. By using the new ...
... a report published in the September issue of the ... programs that advocate quick and short working out sessions ... health conditions that can lead to diseases. To prevent ... and strenuous workout sessions are required every week. ...
... shown that use of general anesthesia for heroin detoxification ... detoxification. The study, which came in the latest issue ... // of general anesthesia in these circumstances can also ... heroin withdrawal remains plagued by patient discomfort and high ...
Cached Medicine News:Health News:WHO declares Tuberculosis – ‘An Emergency’ in Afr 2Health News:Genetic Cause For Farsightedness Discovered 2Health News:Radio-guided Neurosurgery for treatment of Brain cancer 2Health News:General Anesthesia For Heroin Detoxification Is No Good 2
(Date:10/30/2014)... Oct. 30, 2014   NxStage® Kidney Care, Inc ., ... ), is proud to host the grand opening ceremony of ... 1600 W. 16 th Street on November 20, 2014 ... highly trained medical staff who are committed to providing patients ... life benefits made possible through more flexible dialysis treatment options.   ...
(Date:10/30/2014)... , Oct. 30, 2014 Boston Scientific ... participate in the 2014 Credit Suisse Annual Healthcare Conference ... , AZ.  Dan Brennan , executive vice ... about the company beginning at approximately 8:00 a.m. PT ... A live webcast of the presentation and question and ...
(Date:10/30/2014)... Oct. 30, 2014  The number of retail health ... is growing steadily, thanks to drug store chains, according ... of the economic downturn, retail clinic growth had been ... opportunities, as the number of retail clinics reached nearly ... Retail Clinics Market Overview and 2014 Consumer Survey Results ...
Breaking Medicine Technology:Grand Opening of NxStage Kidney Care Oak Brook IL Center 2Grand Opening of NxStage Kidney Care Oak Brook IL Center 3Boston Scientific To Participate In 2014 Credit Suisse Annual Healthcare Conference 2Report: Drugstore Chains Drive Retail Clinic Growth 2Report: Drugstore Chains Drive Retail Clinic Growth 3
... TECH ) financial results for the quarter ended September ... earnings were $27.5 million or $.74 per diluted share.  Adjusted ... $.81 per diluted share after adjustment for intangible asset amortization ... written-up to fair value as part of acquisitions completed in ...
... NEW YORK, Oct. 25, 2011 ... research report is available in its ... Nervous System Disorders Therapeutics Market to ... Disorder and Schizophrenia Accounted for Half ...
Cached Medicine Technology:Techne Corporation Releases Unaudited First Quarter Fiscal Year 2012 Financial Results 2Techne Corporation Releases Unaudited First Quarter Fiscal Year 2012 Financial Results 3Techne Corporation Releases Unaudited First Quarter Fiscal Year 2012 Financial Results 4Techne Corporation Releases Unaudited First Quarter Fiscal Year 2012 Financial Results 5Techne Corporation Releases Unaudited First Quarter Fiscal Year 2012 Financial Results 6Techne Corporation Releases Unaudited First Quarter Fiscal Year 2012 Financial Results 7Techne Corporation Releases Unaudited First Quarter Fiscal Year 2012 Financial Results 8Central Nervous System Disorders Therapeutics Market to 2017 - Multiple Sclerosis, Major Depressive Disorder and Schizophrenia Accounted for Half the Market Value in 2010 2Central Nervous System Disorders Therapeutics Market to 2017 - Multiple Sclerosis, Major Depressive Disorder and Schizophrenia Accounted for Half the Market Value in 2010 3Central Nervous System Disorders Therapeutics Market to 2017 - Multiple Sclerosis, Major Depressive Disorder and Schizophrenia Accounted for Half the Market Value in 2010 4Central Nervous System Disorders Therapeutics Market to 2017 - Multiple Sclerosis, Major Depressive Disorder and Schizophrenia Accounted for Half the Market Value in 2010 5Central Nervous System Disorders Therapeutics Market to 2017 - Multiple Sclerosis, Major Depressive Disorder and Schizophrenia Accounted for Half the Market Value in 2010 6Central Nervous System Disorders Therapeutics Market to 2017 - Multiple Sclerosis, Major Depressive Disorder and Schizophrenia Accounted for Half the Market Value in 2010 7Central Nervous System Disorders Therapeutics Market to 2017 - Multiple Sclerosis, Major Depressive Disorder and Schizophrenia Accounted for Half the Market Value in 2010 8Central Nervous System Disorders Therapeutics Market to 2017 - Multiple Sclerosis, Major Depressive Disorder and Schizophrenia Accounted for Half the Market Value in 2010 9Central Nervous System Disorders Therapeutics Market to 2017 - Multiple Sclerosis, Major Depressive Disorder and Schizophrenia Accounted for Half the Market Value in 2010 10Central Nervous System Disorders Therapeutics Market to 2017 - Multiple Sclerosis, Major Depressive Disorder and Schizophrenia Accounted for Half the Market Value in 2010 11Central Nervous System Disorders Therapeutics Market to 2017 - Multiple Sclerosis, Major Depressive Disorder and Schizophrenia Accounted for Half the Market Value in 2010 12Central Nervous System Disorders Therapeutics Market to 2017 - Multiple Sclerosis, Major Depressive Disorder and Schizophrenia Accounted for Half the Market Value in 2010 13Central Nervous System Disorders Therapeutics Market to 2017 - Multiple Sclerosis, Major Depressive Disorder and Schizophrenia Accounted for Half the Market Value in 2010 14Central Nervous System Disorders Therapeutics Market to 2017 - Multiple Sclerosis, Major Depressive Disorder and Schizophrenia Accounted for Half the Market Value in 2010 15Central Nervous System Disorders Therapeutics Market to 2017 - Multiple Sclerosis, Major Depressive Disorder and Schizophrenia Accounted for Half the Market Value in 2010 16Central Nervous System Disorders Therapeutics Market to 2017 - Multiple Sclerosis, Major Depressive Disorder and Schizophrenia Accounted for Half the Market Value in 2010 17Central Nervous System Disorders Therapeutics Market to 2017 - Multiple Sclerosis, Major Depressive Disorder and Schizophrenia Accounted for Half the Market Value in 2010 18Central Nervous System Disorders Therapeutics Market to 2017 - Multiple Sclerosis, Major Depressive Disorder and Schizophrenia Accounted for Half the Market Value in 2010 19Central Nervous System Disorders Therapeutics Market to 2017 - Multiple Sclerosis, Major Depressive Disorder and Schizophrenia Accounted for Half the Market Value in 2010 20
The DBIL method used on the Dimension clinical chemistry system is an in vitro diagnostic test intended for the quantitative determination of direct (conjugated) bilirubin in serum and plasma....
For the quantitative in vitro determination of Anti-Streptolysin-O (ASO) in serum...
Latex agglutination slide test for the qualitative and semi-quantitative determination of Anti-Streptolysin O (ASO) in human serum...
For the quantitative in vitro determination of IgA in serum and plasma. This product is suitable for use on Hitachi 704, 705, 717, 902, 911 and 912....
Medicine Products: